Global Breast Cancer Monoclonal Antibodies Market Growth 2023-2029

Global Breast Cancer Monoclonal Antibodies Market Growth 2023-2029

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.

LPI (LP Information)' newest research report, the “Breast Cancer Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Breast Cancer Monoclonal Antibodies sales in 2022, providing a comprehensive analysis by region and market sector of projected Breast Cancer Monoclonal Antibodies sales for 2023 through 2029. With Breast Cancer Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Breast Cancer Monoclonal Antibodies industry.

This Insight Report provides a comprehensive analysis of the global Breast Cancer Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Breast Cancer Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Breast Cancer Monoclonal Antibodies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Breast Cancer Monoclonal Antibodies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Breast Cancer Monoclonal Antibodies.

The global Breast Cancer Monoclonal Antibodies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.

This report presents a comprehensive overview, market shares, and growth opportunities of Breast Cancer Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Naked MAbs
Conjugated MAbs

Segmentation by application
Hospitals
Retail Pharmacies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
Roche
Mylan
Array BioPharma
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
Daiichi Sankyo
GlaxoSmithKline
Immunomedics
MacroGenics
Merck
Novartis
Oncothyreon
Pfizer
Puma Biotechnology
Seattle Genetics
Sun Pharmaceutical Industries
Synta Pharmaceuticals
Teva Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Breast Cancer Monoclonal Antibodies market?

What factors are driving Breast Cancer Monoclonal Antibodies market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Breast Cancer Monoclonal Antibodies market opportunities vary by end market size?

How does Breast Cancer Monoclonal Antibodies break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.